Skip to main content

Advertisement

SpringerLink
Log in

Targeted Therapy in Gliomas

  • Neuro-oncology (M Gilbert, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

The survival outcome of patients with malignant gliomas is still poor, despite advances in surgical techniques, radiation therapy and the development of novel chemotherapeutic agents. The heterogeneity of molecular alterations in signaling pathways involved in the pathogenesis of these tumors contributes significantly to their resistance to treatment. Several molecular targets for therapy have been discovered over the last several years. Therapeutic agents targeting these signaling pathways may provide more effective treatments and may improve survival. This review summarizes the important molecular therapeutic targets and the outcome of published clinical trials involving targeted therapeutic agents in glioma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. 1993;3(3):255–68.

    CAS  PubMed  Google Scholar 

  2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.

    CAS  PubMed  Google Scholar 

  3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2–16.

    CAS  PubMed  Google Scholar 

  4. Burgess AW. EGFR family: structure physiology signaling and therapeutic targets. Growth Factors. 2008;26:263–74.

    CAS  PubMed  Google Scholar 

  5. Ekstrand AJ, James CD, Cavenee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51:2164–72.

    CAS  PubMed  Google Scholar 

  6. Pelloski CE, Zhang L, Lin E, et al. EGFRvIII status defines distinct subtypes of glioblastoma: an analysis of 649 cases [abstract]. Neuro-Oncol. 2006;8:462. Abstract PA-26.

    Google Scholar 

  7. Sathornsumetree S, Reardon DA, Desjardins A, et al. Molecularly targeted therapy for malignant glioma. Cancer. 2007;110:13–24.

    Google Scholar 

  8. Pelloski CE, Ballman KV, Furth AF, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol. 2007;25:2288–94.

    CAS  PubMed  Google Scholar 

  9. Barker 2nd FG, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001;51:410–8.

    CAS  PubMed  Google Scholar 

  10. Joensuu H, Puputti M, Sihto H, et al. Amplification of genes encoding KIT, PDGFRα and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme. J Pathol. 2005;207:224–31.

    CAS  PubMed  Google Scholar 

  11. Hermanson M, Funa K, Koopmann J, et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor α receptor expression in human malignant gliomas. Cancer Res. 1996;56:164–71.

    CAS  PubMed  Google Scholar 

  12. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.

    CAS  PubMed Central  PubMed  Google Scholar 

  13. Ranza E, Facoetti A, Morbini P, et al. Exogenous platelet-derived growth factor (PDGF) induces human astrocytoma cell line proliferation. Anticancer Res. 2007;27:2161–6.

    CAS  PubMed  Google Scholar 

  14. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845–8.

    CAS  PubMed  Google Scholar 

  15. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028–43.

    CAS  PubMed  Google Scholar 

  16. Reijneveld JC, Voest EE, Taphoorn MJ. Angiogenesis in malignant primary and metastatic brain tumors. J Neurol. 2000;247:597–608.

    CAS  PubMed  Google Scholar 

  17. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol. 2007;25:1637–8.

    CAS  PubMed  Google Scholar 

  18. Ruegg C, Postigo AA, Sikorski EE, et al. Role of integrin alpha 4 beta 7/alpha 4 beta P inlymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J Cell Biol. 1992;117:179–89.

    CAS  PubMed  Google Scholar 

  19. D’Abaco GM, Kaye AH. Integrins: molecular determinants of glioma invasion. J Clin Neurosci. 2007;14:1041–8.

    PubMed  Google Scholar 

  20. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 2004;22:1926–33.

    CAS  PubMed  Google Scholar 

  21. Wang SI, Puc J, Li J, et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997;57:4183–6.

    CAS  PubMed  Google Scholar 

  22. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63:2742–6.

    CAS  PubMed  Google Scholar 

  23. Couldwell WT, Uhm JH, Antel JP, et al. Enhanced protein kinase C activity correlates with the growth rate of malignant gliomas in vitro. Neurosurgery. 1991;29:880–7.

    CAS  PubMed  Google Scholar 

  24. Fields AP, Tyler G, Kraft AS, et al. Role of nuclear protein kinase C in the mitogenic response to platelet-derived growth factor. J Cell Sci. 1990;96:107–14.

    CAS  PubMed  Google Scholar 

  25. Marais R, Light Y, Mason C, et al. Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C. Science. 1998;280:109–12.

    CAS  PubMed  Google Scholar 

  26. Freed E, Symons M, Macdonald SG, et al. Binding of 14-3–3 proteins to the protein kinase Raf and effects on its activation. Science. 1994;265:1713–6.

    CAS  PubMed  Google Scholar 

  27. Howe L, Leevers S, Gómez N, et al. Activation of the MAP kinase pathway by the protein kinase raf. Cell. 1992;71:335–42.

    CAS  PubMed  Google Scholar 

  28. Knobbe CB, Reifenberger J, Reifenberger G. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (Berl). 2004;108:467–70.

    CAS  Google Scholar 

  29. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–30.

    CAS  PubMed  Google Scholar 

  30. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006;12:3935–41.

    CAS  PubMed  Google Scholar 

  31. Lu KV, Zhu S, Cvrljevic A, et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009;69:6889–98.

    CAS  PubMed Central  PubMed  Google Scholar 

  32. Du J, Bernasconi P, Clauser KR, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009;27:77–83.

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Toschi L, Janne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res. 2008;14:5941–6.

    CAS  PubMed  Google Scholar 

  34. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140–8.

    PubMed  Google Scholar 

  35. Gray S, Ekström T. The human histone deacetylase family. Exp Cell Res. 2001;262:75–83.

    CAS  PubMed  Google Scholar 

  36. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210–6.

    CAS  PubMed  Google Scholar 

  37. Yoshida M, Horinouchi S, Beppu T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioessays. 1995;17:423–30.

    CAS  PubMed  Google Scholar 

  38. Kesari S, Ramakrishna N, Sauvageot C, et al. Targeted molecular therapy of malignant gliomas. Curr Oncol Rep. 2006;8:58–70.

    CAS  PubMed  Google Scholar 

  39. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349–60.

    CAS  PubMed  Google Scholar 

  40. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8:808–15.

    CAS  PubMed  Google Scholar 

  41. Kleber S, Sancho-Martinez I, Wiestler B, et al. Yes and PI3K bind CD95 to signal invasion of glioblastoma. Cancer Cell. 2008;13:235–48.

    CAS  PubMed  Google Scholar 

  42. Assimakopoulou M, Varakis J. AP-1 and heat shock protein 27 expression in human astrocytomas. J Cancer Res Clin Oncol. 2001;127(12):727–32.

    CAS  PubMed  Google Scholar 

  43. Graner MW, Bigner DD. Chaperone proteins and brain tumors: potential targets and possible therapeutics. Neuro Oncol. 2005;7:260–78.

    CAS  PubMed Central  PubMed  Google Scholar 

  44. Premkumar D, Arnold B, Pollack I. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth. Mol Carcinog. 2006;45:288–301.

    CAS  PubMed  Google Scholar 

  45. Powell C, Mikropoulos C, Kaye SB, et al. Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitizers. Cancer Treat Rev. 2010;36:566–75.

    CAS  PubMed  Google Scholar 

  46. Galia A, Calogero AE, Condorelli R, et al. PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem. 2012;56(1):e9.

    CAS  PubMed Central  PubMed  Google Scholar 

  47. Chinnaiyan P, Won M, Wen PY, et al. RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2013;86(5):880–4.

    CAS  PubMed  Google Scholar 

  48. Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase ½ study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85(5):1206–11.

    CAS  PubMed  Google Scholar 

  49. Franceschi E, Stupp R, van den Bent MJ, et al. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma. Neuro Oncol. 2012;12(12):1503–10.

    Google Scholar 

  50. Kesavabhotla K, Schlaff CD, Shin B, et al. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. J Exp Ther Oncol. 2012;10(1):71–81.

    CAS  PubMed  Google Scholar 

  51. Lee EQ, Puduvalli VK, Reid JM, et al. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012;18(21):6032–9.

    CAS  PubMed  Google Scholar 

  52. Moller S, Grunnet K, Hansen S, et al. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012;51(6):797–804.

    CAS  PubMed  Google Scholar 

  53. Rampling R, Sanson M, Gorlia T, et al. A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro Oncol. 2012;14(3):344–50.

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Mason WP, Macneil M, Kavan P, et al. A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study. Invest New Drugs. 2012;30(6):2344–51.

    CAS  PubMed  Google Scholar 

  55. Mason WP, Belanger K, Nicholas G, et al. A phase II study of the Ras-MAPK signaling pathway inhibitor TLN-4601 in patients with glioblastoma at first progression. J Neurooncol. 2012;107(2):343–9.

    CAS  PubMed  Google Scholar 

  56. Reardon DA, Desjardins A, Peters KB, et al. Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol. 2012;107(1):155–64.

    CAS  PubMed Central  PubMed  Google Scholar 

  57. Butowski N, Chang SM, Lamborn KR, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol. 2011;13(12):1331–8.

    PubMed Central  PubMed  Google Scholar 

  58. Gilbert MR, Kuhn J, Lamborn KR, et al. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012;106(1):147–53.

    CAS  PubMed  Google Scholar 

  59. Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011;117(23):5351–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  60. Vredenburgh JJ, Desjardins A, Reardon DA, et al. The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res. 2011;17(12):4119–24.

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Iwamoto FM, Lamborn KR, Kuhn JG, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03. Neuro Oncol. 2011;13(5):509–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011;13(4):437–46.

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13(1):132–42.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Nghiemphu PL, Wen PY, Lamborn KR, et al. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Phys. 2011;81(5):1422–7.

    CAS  Google Scholar 

  65. Sarkaria JN, Galanis E, Wu W, et al. Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res. 2010;16(22):5573–80.

    CAS  PubMed Central  PubMed  Google Scholar 

  66. Sarkaria JN, Galanis E, Wu W, et al. North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2011;81(2):468–75.

    CAS  PubMed Central  PubMed  Google Scholar 

  67. Yung WK, Vredenburgh JJ, Cloughesy TF, et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol. 2010;12(10):1061–70.

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347–53.

    CAS  PubMed  Google Scholar 

  69. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of Cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010;28(17):2817–23.

    CAS  PubMed Central  PubMed  Google Scholar 

  70. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(16):2712–8.

    CAS  PubMed  Google Scholar 

  71. Li L, Quang TS, Gracely EJ, et al. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010;113(2):192–8.

    PubMed  Google Scholar 

  72. Phuphanich S, Supko JG, Carson KA, et al. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurooncol. 2010;100(1):95–103.

    CAS  PubMed  Google Scholar 

  73. Butowski N, Chang SM, Lamborn KR, et al. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol. 2010;12(6):608–13.

    CAS  PubMed Central  PubMed  Google Scholar 

  74. Kreisl TN, Kotliarova S, Butman JA, et al. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol. 2010;12(2):181–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  75. Raizer JJ, Abrey LE, Lassman AB, et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010;12(1):95–103.

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Raizer JJ, Abrey LE, Lassman AB, et al. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010;12(1):87–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Reardon DA, Desjardins A, Peters K, et al. Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. J Neurooncol. 2011;103(2):371–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Lai A, Tran A, Nghiemphu PL, et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011;29(2):142–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  79. Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722–9.

    PubMed Central  PubMed  Google Scholar 

  80. Narayana A, Gruber D, Kunnakkat S, et al. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg. 2012;116(2):341–5.

    CAS  PubMed  Google Scholar 

  81. Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer. 2012;118(5):1302–12.

    CAS  PubMed  Google Scholar 

  82. Nabors LB, Mikkelsen T, Hegi ME, et al. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012;118(22):5601–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Nagane M, Nishikawa R, Narita Y, et al. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma. Jpn J Clin Oncol. 2012;42(10):887–95.

    PubMed Central  PubMed  Google Scholar 

  84. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7):1168–74.

    CAS  PubMed Central  PubMed  Google Scholar 

  85. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93–9.

    CAS  PubMed  Google Scholar 

  86. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101(12):1986–94.

    CAS  PubMed Central  PubMed  Google Scholar 

  87. Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–40.

    CAS  PubMed  Google Scholar 

  89. Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol. 2009;27(25):4155–61.

    CAS  PubMed Central  PubMed  Google Scholar 

  90. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoam multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65(2):353–61.

    CAS  PubMed  Google Scholar 

  91. Galanis E, Jaeckle KA, Maurer MJ, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol. 2009;27(12):2052–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  92. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–5.

    CAS  PubMed Central  PubMed  Google Scholar 

  93. Kubicek GJ, Werner-Wasik M, Machtay M, et al. Phase I trial using proteasome inhibitor botezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys. 2009;74(2):433–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  94. Prados MD, Chang SM, Butowski N, et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. J Clin Oncol. 2009;27(4):579–84.

    CAS  PubMed Central  PubMed  Google Scholar 

  95. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008;26(34):5610–7.

    CAS  PubMed  Google Scholar 

  96. Brown PD, Krishnan S, Sarkaria JN, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol. 2008;26(34):5603–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  97. da Fonseca CO, Linden R, Futuro D, et al. Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol. Arch Immunol Ther Exp (Warsz). 2008;56(4):267–76.

    Google Scholar 

  98. Lustig R, Mikkelsen T, Lesser G, et al. Phase II preradiation R115777 (tipifarnib) in newly diagnosed GBM with residual enhancing disease. Neuro Oncol. 2008;10(6):1004–9.

    CAS  PubMed Central  PubMed  Google Scholar 

  99. De Groot JF, Gilbert MR, Aldape K, et al. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. J Neurooncol. 2008;90(1):89–97.

    PubMed  Google Scholar 

  100. Phuphanich S, Carson KA, Grossman SA, et al. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol. 2008;10(4):617–23.

    CAS  PubMed Central  PubMed  Google Scholar 

  101. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372–80.

    CAS  PubMed  Google Scholar 

  102. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5(1):e8.

    PubMed Central  PubMed  Google Scholar 

  103. Casaco A, Lopez G, Garcia I, et al. Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188 Re in adult recurrent high-grade glioma. Cancer Biol Ther. 2008;7(3):333–9.

    CAS  PubMed  Google Scholar 

  104. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722–9.

    CAS  PubMed  Google Scholar 

  105. Moyal EC, Laprie A, Delannes M, et al. Phase I trial of tipirafinib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2007;68(5):1396–401.

    PubMed  Google Scholar 

  106. Franceschi E, Cavallo G, Lonardi S, et al. Gefitinib in patients with progressive high-grade gliomas: a multicenter phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer. 2007;96:1047–51.

    CAS  PubMed Central  PubMed  Google Scholar 

  107. Cloughesy TF, Wen PY, Robins HI, et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006;24(22):3651–6.

    CAS  PubMed  Google Scholar 

  108. Levin VA, Phuphanich S, Yung WK, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006;78(3):295–302.

    CAS  PubMed  Google Scholar 

  109. Krishnan S, Brown PD, Ballman KV, et al. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys. 2006;65(4):1192–9.

    CAS  PubMed  Google Scholar 

  110. Ramos TC, Figueredo J, Catala M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h0R3: report from a phase I/II trial. Cancer Biol Ther. 2006;5(4):375–9.

    CAS  PubMed  Google Scholar 

  111. Prados MD, Lamborn KR, Chang S, et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006;8(1):67–78.

    CAS  PubMed Central  PubMed  Google Scholar 

  112. Chang SM, Wen P, Cloughesy T, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23(4):357–61.

    CAS  PubMed  Google Scholar 

  113. Galanis E, Buckner JC, Maurer MJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol. 2005;23(23):5294–304.

    CAS  PubMed  Google Scholar 

  114. Haas-Kogan DA, Prados MD, Tihan T, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005;97(12):880–7.

    CAS  PubMed  Google Scholar 

  115. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22(1):133–42.

    CAS  PubMed  Google Scholar 

  116. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol. 2002;20(5):1383–8.

    CAS  PubMed  Google Scholar 

  117. Stragliotto G, Vega F, Stasiecki P, et al. Multiple infusions of anti-epidermal growth factor recedptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996;32A(4):636–40.

    CAS  PubMed  Google Scholar 

  118. Snelling L, Miyamoto CT, Bender H, et al. Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma. 1995;14(2):111–4.

    CAS  PubMed  Google Scholar 

  119. Brady LW, Miyamoto C, Woo DV, et al. Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys. 1992;22(1):225–30.

    CAS  PubMed  Google Scholar 

  120. Zustovich F, Landi L, Lombardi G, et al. Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. Anticancer Res. 2013;33(8):3487–94.

    CAS  PubMed  Google Scholar 

  121. Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme. Anticancer Res. 2013;33(4):1657–60.

    CAS  PubMed  Google Scholar 

  122. Reardon DA, Groves MD, Wen PY, et al. A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res. 2013;19(4):900–8.

    CAS  PubMed  Google Scholar 

  123. Peereboom DM, Ahluwalia MS, Ye X, et al. NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2013;15(4):490–6.

    CAS  PubMed  Google Scholar 

  124. Muhic A, Poulsen HS, Sorensen M, et al. Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme. J Neurooncol. 2013;111(2):205–12.

    CAS  PubMed  Google Scholar 

  125. D’Alessandri QG, Montano N, Cenci T, et al. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience. Acta Neurochir (Wien). 2013;155(1):33–40.

    Google Scholar 

  126. Kreisl TN, McNeill KA, Sul J, et al. A phase I/II trial of vandetanib for patients with recurrent malignant glioma. Neuro Oncol. 2012;14(12):1519–26.

    CAS  PubMed Central  PubMed  Google Scholar 

  127. Lee EQ, Kuhn J, Lamborn KR, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012;14(12):1511–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  128. Kreisl TN, Smith P, Sul J, et al. Continuous daily sunitinib for recurrent glioblastoma. J Neurooncol. 2013;111(1):41–8.

    CAS  PubMed  Google Scholar 

  129. Alexander BM, Wang M, Yung WK, et al. A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806). J Neurooncol. 2013;111(1):33–9.

    CAS  PubMed  Google Scholar 

  130. Nghiemphu PL, Lai A, Green RM, et al. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J Neurooncol. 2012;110(2):245–50.

    CAS  PubMed Central  PubMed  Google Scholar 

  131. Pan E, Yu D, Yue B, et al. A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol. 2012;110(1):111–8.

    CAS  PubMed  Google Scholar 

  132. Hainsworth JD, Shih KC, Shepard GC, et al. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol. 2012;10(4):240–6.

    PubMed  Google Scholar 

  133. Reardon DA, Conrad CA, Cloughesy T, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012;69(6):1507–18.

    CAS  PubMed  Google Scholar 

  134. Friday BB, Anderson SK, Buckner J, et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. Neuro Oncol. 2012;14(2):215–21.

    CAS  PubMed Central  PubMed  Google Scholar 

  135. Giglio P, Dhamne M, Hess KR, et al. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 2012;118(14):3599–606.

    CAS  PubMed  Google Scholar 

  136. Chinnaiyan P, Chowdhary S, Potthast L, et al. Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma. Neuro Oncol. 2012;14(1):93–100.

    CAS  PubMed Central  PubMed  Google Scholar 

  137. Reardon DA, Vredenburgh JJ, Coan A, et al. Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. J Neurooncol. 2011;105(3):621–7.

    CAS  PubMed Central  PubMed  Google Scholar 

  138. De Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19):2689–95.

    PubMed Central  PubMed  Google Scholar 

  139. Gerstner ER, Eichler AF, Plotkin SR, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011;103(2):325–32.

    CAS  PubMed  Google Scholar 

  140. Gilbert MR, Gonzalez J, Hunter K, et al. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro Oncol. 2010;12(11):1167–72.

    CAS  PubMed Central  PubMed  Google Scholar 

  141. Sathornsumetee S, Dejardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12(12):1300–10.

    CAS  PubMed Central  PubMed  Google Scholar 

  142. Hainsworth JD, Ervin T, Friedman E, et al. Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 2010;116(15):3663–9.

    CAS  PubMed  Google Scholar 

  143. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010;12(5):508–16.

    CAS  PubMed Central  PubMed  Google Scholar 

  144. Nabors LB, Fiveash JB, Markert JM, et al. A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol. 2010;67(3):313–9.

    PubMed  Google Scholar 

  145. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol. 2010;12(8):8555–61.

    Google Scholar 

  146. Drappatz J, Norden AD, Wong ET, et al. Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2010;78(1):85–90.

    CAS  PubMed  Google Scholar 

  147. Brandes AA, Stupp R, Hau P, et al. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. Eur J Cancer. 2010;46(2):348–54.

    CAS  PubMed  Google Scholar 

  148. Reardon DA, Dresemann G, Taillibert S, et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer. 2009;101(12):1995–2004.

    CAS  PubMed Central  PubMed  Google Scholar 

  149. Razis E, Selviaridis P, Labropoulos S, et al. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res. 2009;15(19):6258–66.

    CAS  PubMed  Google Scholar 

  150. Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol. 2010;96(3):393–402.

    CAS  PubMed  Google Scholar 

  151. Reardon DA, Desjardin A, Vredenburgh JJ, et al. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol. 2010;96(2):219–30.

    CAS  PubMed Central  PubMed  Google Scholar 

  152. Reardon DA, Egorin MJ, Desjardins A, et al. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009;115(10):2188–98.

    CAS  PubMed Central  PubMed  Google Scholar 

  153. Kreisl TN, Lassman AB, Mischel PS, et al. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol. 2009;92(1):99–105.

    CAS  PubMed  Google Scholar 

  154. Fadul CE, Kingman LS, Meyer LP, et al. A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme. J Neurooncol. 2008;90(2):229–35.

    CAS  PubMed  Google Scholar 

  155. Drappatz J, Wong ET, Schiff D, et al. A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Phys. 2009;73(1):222–7.

    CAS  Google Scholar 

  156. Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 2008;10(3):300–8.

    CAS  PubMed Central  PubMed  Google Scholar 

  157. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol. 2008;10(3):330–40.

    CAS  PubMed Central  PubMed  Google Scholar 

  158. Puduvalli VK, Giglio P, Groves MD, et al. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro Oncol. 2008;10(2):216–22.

    CAS  PubMed Central  PubMed  Google Scholar 

  159. Fine HA, Kim L, Albert PS, et al. A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors. Clin Cancer Res. 2007;13(23):7101–6.

    CAS  PubMed  Google Scholar 

  160. Zustovich F, Cartei G, Ceravolo R, et al. A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors. Anticancer Res. 2007;27(2):1019–24.

    CAS  PubMed  Google Scholar 

  161. Desjardins A, Quinn JA, Vredenburgh JJ, et al. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol. 2007;83(1):53–60.

    CAS  PubMed  Google Scholar 

  162. Groves MD, Puduvalli VK, Chang SM, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007;81(3):271–7.

    CAS  PubMed  Google Scholar 

  163. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006;12(16):4899–907.

    CAS  PubMed  Google Scholar 

  164. Reardon DA, Quinn JA, Vredenburgh JJ, et al. Phase I trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res. 2006;12(3 Pt 1):860–8.

    CAS  PubMed  Google Scholar 

  165. Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol. 2005;23(36):9359–68.

    CAS  PubMed  Google Scholar 

  166. Chang SM, Lamborn KR, Malec M, et al. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2004;60(2):353–7.

    CAS  PubMed  Google Scholar 

  167. Baumann F, Bjeljac M, Kollias SS, et al. Combined thalidomide and temozolomide treatment in patients with glioblastoma multiforme. J Neurooncol. 2004;67(1–2):191–200.

    PubMed  Google Scholar 

  168. Morabito A, Fanelli M, Carillio G, et al. Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma. Oncol Rep. 2004;11(1):93–5.

    CAS  PubMed  Google Scholar 

  169. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003;21(12):2299–304.

    CAS  PubMed  Google Scholar 

  170. Marx GM, Pavlakis N, McCowatt S, et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol. 2001;54(1):31–8.

    CAS  PubMed  Google Scholar 

  171. Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000;18(4):708–15.

    CAS  PubMed  Google Scholar 

  172. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.

    Google Scholar 

  173. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62(1):200–7.

    CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Mohamed Ali Hamza and Mark Gilbert declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Mohamed Ali Hamza & Mark Gilbert

Authors
  1. Mohamed Ali Hamza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Ali Hamza.

Additional information

This article is part of the Topical Collection on Neuro-oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hamza, M.A., Gilbert, M. Targeted Therapy in Gliomas. Curr Oncol Rep 16, 379 (2014). https://doi.org/10.1007/s11912-014-0379-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-014-0379-z

Keywords

Search

Navigation